The proposed Mayo Clinic SPORE in Pancreatic Cancer will facilitate and promote research in pancreatic cancer that is highly likely to result in benefit to patients who currently have very little hope or treatment options. With a paucity of research in pancreatic cancer, our emphasis is on the discovery of novel mechanisms and pathways that will elucidate the etiology and pathogenesis of pancreatic carcinoma, which in turn can translate into strategies for prevention, early detection, and treatment. Led by senior pancreatic cancer researchers, our SPORE has a significant research and patient base. Annually, physicians at Mayo Clinic see approximately 450 patients with pancreatic cancer, which alone constitutes 1.5% of all pancreatic cancer cases in the United States. All of the proposed projects have a scientific base with a translational trajectory. Project #1 will provide one of the most definitive means to study the role of candidate genes and environment in the etiology of pancreatic adenocarcinoma. Project #2 will include both a retrospective cohort study to characterize the optimal criteria for screening diabetic patients with undiagnosed pancreatic cancer and identify markers that discriminate patients with diabetes mellitus that is apparently caused by pancreatic cancer. Project #3 will examine the mechanisms of action and role of Vavl protooncogene in pancreatic cancer. Project #4 will examine the role of the mechanism and role of the BRCA2 gene in pancreatic cancer. Project #5 will utilize transgenic animal models of pancreatic cancer to evaluate therapeutic combinations of vaccine, COX-2 inhibitors, and chemo/radiation. We will make particular efforts to encourage pilot studies that utilize the core resources to understand pancreatic cancer. Following a formal, rigorous review process, this SPORE will thus fund up to six developmental projects annually. We will support career development of junior faculty who will be expected to build independent programs in translational pancreatic cancer research. Four cores Administrative Core, Patient Registry and Biospecimens Core, Animal Models and Xenograft Core, and Biostatistics Core) will support the research projects. An External Advisory Committee and internal Scientific Advisory Committee will provide scientific input and guidance, and broad institutional support will enhance the infrastructure of this SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA102701-01
Application #
6675260
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2003-09-29
Project End
2008-08-31
Budget Start
2003-09-29
Budget End
2004-08-31
Support Year
1
Fiscal Year
2003
Total Cost
$1,500,000
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10
Chini, Eduardo N; Chini, Claudia C S; Espindola Netto, Jair Machado et al. (2018) The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging. Trends Pharmacol Sci 39:424-436
Kim, Jungsun; Bamlet, William R; Oberg, Ann L et al. (2017) Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med 9:
Espindola-Netto, Jair Machado; Chini, Claudia C S; Tarragó, Mariana et al. (2017) Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget 8:85054-85067
Ding, Li; Liou, Geou-Yarh; Schmitt, Daniel M et al. (2017) Glycogen synthase kinase-3? ablation limits pancreatitis-induced acinar-to-ductal metaplasia. J Pathol 243:65-77
Cho, Dong Seong; Doles, Jason D (2017) Single cell transcriptome analysis of muscle satellite cells reveals widespread transcriptional heterogeneity. Gene 636:54-63
Luo, Kuntian; Li, Yunhui; Yin, Yujiao et al. (2017) USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J 36:1434-1446

Showing the most recent 10 out of 52 publications